Picture loading failed.

Anti-PDL1 therapeutic antibody (Pre-made Sugemalimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Sugemalimab is an investigational anti-programmed cell death ligand 1 (PD-L1) monoclonal antibody. It mimics the natural G-type immunoglobulin 4 human antibody, which lowers immunogenicity and possible toxicity risks.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-534-1mg 1mg 3090
GMP-Bios-ab-534-10mg 10mg 21890
GMP-Bios-ab-534-100mg 100mg 148000
GMP-Bios-ab-534-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-PDL1 therapeutic antibody (Pre-made Sugemalimab biosimilar,Whole mAb)
INN Name Sugemalimab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusPreregistration
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesCstone Pharmaceuticals
Conditions Approvedna
Conditions ActiveCancers;Non-small Cell Lung Cancer;T-cell Lymphoma;Solid tumours;Hodgkin Lymphoma;Gastric cancer
Conditions Discontinuedna
Development Techna